EA201491456A1 - RAF INHIBITOR COMPOUNDS - Google Patents
RAF INHIBITOR COMPOUNDSInfo
- Publication number
- EA201491456A1 EA201491456A1 EA201491456A EA201491456A EA201491456A1 EA 201491456 A1 EA201491456 A1 EA 201491456A1 EA 201491456 A EA201491456 A EA 201491456A EA 201491456 A EA201491456 A EA 201491456A EA 201491456 A1 EA201491456 A1 EA 201491456A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- inhibitor compounds
- raf inhibitor
- raf
- pyrido
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
Abstract
В настоящем изобретении предложено пиридо[2,3-d]пиримидиновое соединение или его фармацевтически приемлемая соль, ингибирующее Raf, которое, таким образом, может подходить для лечения рака.The present invention provides a pyrido [2,3-d] pyrimidine compound or a pharmaceutically acceptable salt thereof inhibiting Raf, which may thus be suitable for treating cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607702P | 2012-03-07 | 2012-03-07 | |
| PCT/US2013/029084 WO2013134243A1 (en) | 2012-03-07 | 2013-03-05 | 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201491456A1 true EA201491456A1 (en) | 2014-12-30 |
| EA024824B1 EA024824B1 (en) | 2016-10-31 |
Family
ID=47884613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201491456A EA024824B1 (en) | 2012-03-07 | 2013-03-05 | Raf inhibitors compounds |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US8741911B2 (en) |
| EP (1) | EP2850082B1 (en) |
| JP (1) | JP2015509536A (en) |
| KR (1) | KR20140129087A (en) |
| CN (1) | CN104302646B (en) |
| AP (1) | AP2014007899A0 (en) |
| AR (1) | AR090151A1 (en) |
| AU (1) | AU2013230146B2 (en) |
| BR (1) | BR112014018528A8 (en) |
| CA (1) | CA2863673A1 (en) |
| CL (1) | CL2014002220A1 (en) |
| CO (1) | CO7010837A2 (en) |
| CR (1) | CR20140378A (en) |
| CY (1) | CY1117846T1 (en) |
| DK (1) | DK2850082T3 (en) |
| DO (1) | DOP2014000200A (en) |
| EA (1) | EA024824B1 (en) |
| EC (1) | ECSP14017584A (en) |
| ES (1) | ES2584387T3 (en) |
| HK (1) | HK1202541A1 (en) |
| HR (1) | HRP20160654T1 (en) |
| HU (1) | HUE028095T2 (en) |
| IL (1) | IL234052A (en) |
| IN (1) | IN2014MN01575A (en) |
| LT (1) | LT2850082T (en) |
| MA (1) | MA37316B1 (en) |
| ME (1) | ME02423B (en) |
| MX (1) | MX2014010701A (en) |
| NZ (1) | NZ627454A (en) |
| PE (1) | PE20142338A1 (en) |
| PH (1) | PH12014501986B1 (en) |
| PT (1) | PT2850082T (en) |
| RS (1) | RS54840B1 (en) |
| SG (1) | SG11201404969YA (en) |
| SI (1) | SI2850082T1 (en) |
| TN (1) | TN2014000375A1 (en) |
| TW (1) | TW201348233A (en) |
| UA (1) | UA112340C2 (en) |
| WO (2) | WO2013134252A1 (en) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR090151A1 (en) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | RAF INHIBITING COMPOUNDS |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| TWI704151B (en) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Erk inhibitors |
| JP2019517549A (en) * | 2016-06-10 | 2019-06-24 | ノバルティス アーゲー | Therapeutic use of C-RAF inhibitors |
| WO2018115380A1 (en) | 2016-12-22 | 2018-06-28 | Boehringer Ingelheim International Gmbh | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| WO2018200981A1 (en) * | 2017-04-28 | 2018-11-01 | Quartz Therapeutics, Inc. | Raf-degrading conjugate compounds |
| LT3728254T (en) | 2017-12-21 | 2023-05-10 | Boehringer Ingelheim International Gmbh | Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors |
| JP7161849B2 (en) * | 2018-01-24 | 2022-10-27 | 株式会社クラレ | Method for producing primary amine |
| JP2022500385A (en) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | Combination therapy |
| EP3902547B1 (en) | 2018-12-28 | 2023-09-20 | Deciphera Pharmaceuticals, LLC | Csf1r inhibitors for use in treating cancer |
| CN113692304A (en) | 2019-02-06 | 2021-11-23 | 礼来公司 | 1- ((2- (2,2, 2-trifluoroethoxy) pyridin-4-yl) methyl) urea derivatives as KCNQ enhancers |
| TW202106684A (en) | 2019-05-03 | 2021-02-16 | 美商奇奈特生物製藥公司 | Inhibitors of raf kinases |
| JP2022531801A (en) | 2019-05-10 | 2022-07-11 | デシフェラ・ファーマシューティカルズ，エルエルシー | Phenylaminopyrimidine amide autophagy inhibitor and how to use it |
| CN114072397A (en) | 2019-05-10 | 2022-02-18 | 德西费拉制药有限责任公司 | Heteroaryl aminopyrimidine amide autophagy inhibitors and methods of use thereof |
| MX2021015628A (en) | 2019-06-17 | 2022-04-18 | Deciphera Pharmaceuticals Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof. |
| MX2022001863A (en) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Ripretinib for treating gastrointestinal stromal tumors. |
| TW202122082A (en) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | Methods of treating gastrointestinal stromal tumors |
| IL293864A (en) | 2019-12-30 | 2022-08-01 | Deciphera Pharmaceuticals Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| LT4084778T (en) | 2019-12-30 | 2024-01-25 | Deciphera Pharmaceuticals, Llc | Amorphous kinase inhibitor formulations and methods of use thereof |
| CN116034106A (en) | 2020-06-02 | 2023-04-28 | 勃林格殷格翰国际有限公司 | Cyclic 2-amino-3-cyanothiophenes and derivatives for the treatment of cancer |
| US11407737B2 (en) | 2020-09-18 | 2022-08-09 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| US11377431B2 (en) | 2020-10-12 | 2022-07-05 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| US20220133734A1 (en) | 2020-11-02 | 2022-05-05 | Boehringer Ingelheim International Gmbh | Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors |
| IL302807A (en) | 2020-11-18 | 2023-07-01 | Deciphera Pharmaceuticals Llc | Gcn2 and perk kinase inhibitors and methods of use thereof |
| CN117396472A (en) | 2020-12-22 | 2024-01-12 | 上海齐鲁锐格医药研发有限公司 | SOS1 inhibitors and uses thereof |
| CN117561057A (en) | 2021-04-23 | 2024-02-13 | 金耐特生物制药公司 | Treatment of cancer with RAF inhibitors |
| US20220388986A1 (en) | 2021-04-29 | 2022-12-08 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
| WO2023099592A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2023099620A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes |
| WO2023099608A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2023099612A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| TW202340208A (en) | 2021-12-01 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| TW202337431A (en) | 2021-12-01 | 2023-10-01 | 德商百靈佳殷格翰國際股份有限公司 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| TW202342442A (en) | 2021-12-09 | 2023-11-01 | 美商迪賽孚爾製藥有限公司 | Raf kinase inhibitors and methods of use thereof |
| WO2023118250A1 (en) | 2021-12-23 | 2023-06-29 | Boehringer Ingelheim International Gmbh | 8-aza quinazolines as brain-penetrant sos1-inhibitors |
| WO2023173017A1 (en) * | 2022-03-09 | 2023-09-14 | Blossomhill Therapeutics, Inc. | Kras inhibitors for treating disease |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4383870B2 (en) * | 2001-10-17 | 2009-12-16 | 協和発酵キリン株式会社 | Quinoline derivatives and quinazoline derivatives that inhibit fibroblast growth factor receptor autophosphorylation and pharmaceutical compositions containing them |
| JPWO2004039782A1 (en) * | 2002-10-29 | 2006-03-02 | 麒麟麦酒株式会社 | Quinoline derivatives and quinazoline derivatives that inhibit Flt3 autophosphorylation and pharmaceutical compositions containing them |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| US8901137B2 (en) * | 2010-02-09 | 2014-12-02 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors |
| AR090151A1 (en) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | RAF INHIBITING COMPOUNDS |
-
2013
- 2013-02-26 AR ARP130100576A patent/AR090151A1/en unknown
- 2013-02-27 TW TW102107122A patent/TW201348233A/en unknown
- 2013-03-05 AU AU2013230146A patent/AU2013230146B2/en not_active Ceased
- 2013-03-05 ES ES13712005.1T patent/ES2584387T3/en active Active
- 2013-03-05 US US13/785,575 patent/US8741911B2/en not_active Expired - Fee Related
- 2013-03-05 EA EA201491456A patent/EA024824B1/en not_active IP Right Cessation
- 2013-03-05 MA MA37316A patent/MA37316B1/en unknown
- 2013-03-05 NZ NZ627454A patent/NZ627454A/en not_active IP Right Cessation
- 2013-03-05 BR BR112014018528A patent/BR112014018528A8/en not_active IP Right Cessation
- 2013-03-05 MX MX2014010701A patent/MX2014010701A/en unknown
- 2013-03-05 KR KR1020147024732A patent/KR20140129087A/en active IP Right Grant
- 2013-03-05 RS RS20160416A patent/RS54840B1/en unknown
- 2013-03-05 LT LTEP13712005.1T patent/LT2850082T/en unknown
- 2013-03-05 IN IN1575MUN2014 patent/IN2014MN01575A/en unknown
- 2013-03-05 EP EP13712005.1A patent/EP2850082B1/en active Active
- 2013-03-05 WO PCT/US2013/029098 patent/WO2013134252A1/en active Application Filing
- 2013-03-05 JP JP2014561029A patent/JP2015509536A/en not_active Ceased
- 2013-03-05 CA CA2863673A patent/CA2863673A1/en not_active Abandoned
- 2013-03-05 AP AP2014007899A patent/AP2014007899A0/en unknown
- 2013-03-05 US US14/383,799 patent/US9334267B2/en not_active Expired - Fee Related
- 2013-03-05 CN CN201380012913.9A patent/CN104302646B/en not_active Expired - Fee Related
- 2013-03-05 SG SG11201404969YA patent/SG11201404969YA/en unknown
- 2013-03-05 PE PE2014001381A patent/PE20142338A1/en not_active Application Discontinuation
- 2013-03-05 DK DK13712005.1T patent/DK2850082T3/en active
- 2013-03-05 WO PCT/US2013/029084 patent/WO2013134243A1/en active Application Filing
- 2013-03-05 ME MEP-2016-124A patent/ME02423B/en unknown
- 2013-03-05 PT PT137120051T patent/PT2850082T/en unknown
- 2013-03-05 HU HUE13712005A patent/HUE028095T2/en unknown
- 2013-03-05 SI SI201330188A patent/SI2850082T1/en unknown
- 2013-05-03 UA UAA201409109A patent/UA112340C2/en unknown
-
2014
- 2014-07-24 CO CO14161404A patent/CO7010837A2/en unknown
- 2014-08-11 IL IL234052A patent/IL234052A/en not_active IP Right Cessation
- 2014-08-12 CR CR20140378A patent/CR20140378A/en unknown
- 2014-08-21 CL CL2014002220A patent/CL2014002220A1/en unknown
- 2014-09-03 TN TNP2014000375A patent/TN2014000375A1/en unknown
- 2014-09-04 DO DO2014000200A patent/DOP2014000200A/en unknown
- 2014-09-05 PH PH12014501986A patent/PH12014501986B1/en unknown
- 2014-09-05 EC ECIEPI201417584A patent/ECSP14017584A/en unknown
-
2015
- 2015-03-26 HK HK15103082.6A patent/HK1202541A1/en unknown
-
2016
- 2016-06-10 HR HRP20160654TT patent/HRP20160654T1/en unknown
- 2016-07-22 CY CY20161100719T patent/CY1117846T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201491456A1 (en) | RAF INHIBITOR COMPOUNDS | |
| PH12016500676A1 (en) | Pyrimidine fgfr4 inhibitors | |
| PH12016500169A1 (en) | Polymorph of syk inhibitors | |
| PL2922828T3 (en) | 4,6-diamino-pyrimidine derivatives as bmi-1 inhibitors for treating cancer | |
| MX361499B (en) | Deuterated baricitinib. | |
| SI2857404T1 (en) | IMIDAZO(1,2-b)PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | |
| UY34156A (en) | METALOENZYM INHIBITING COMPOUNDS | |
| CR20140229A (en) | NEW BICYCLIC DERIVATIVES OF DIHIDROISOQUINOLIN-1-ONA | |
| NI201800042A (en) | NEW DERIVATIVES OF PIRROLO [2,3-D] PYRIMIDINE AS DUAL INHIBITORS OF DYRK1 / CLK1 | |
| MX339192B (en) | Heterocyclic compounds useful for kinase inhibition. | |
| MX355728B (en) | Kinase inhibitors. | |
| IN2015DN00598A (en) | ||
| HK1223923A1 (en) | 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer idh2 24- 46- | |
| HK1209277A1 (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors 124--6- | |
| IN2014DN07996A (en) | ||
| MX2015008829A (en) | Deuterated momelotinib. | |
| DK3083627T3 (en) | [1,2,4] TRIAZOL [1,5-A] PYRIMIDINE DERIVATIVES AS PROTOZOIC PROTEASOMIN INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES, SUCH AS LEISHMANIASIS | |
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| MX2015012610A (en) | Deuterated pacritinib. | |
| HK1251232A1 (en) | Pyrrolo[2,3-d]pyrimidine compound or salt thereof | |
| TW201613928A (en) | Vinyl compounds as inhibitors for FGFR and VEGFR | |
| CO6650412A2 (en) | Process for the preparation of 8-alkoxy [1.2.4] triazole [1.5-c] substituted pyrimidin-2-amines -5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |